Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (108... von Dekker, T. J. A., van de Velde, C. J. H., van Pelt, G. W., Kroep, J. R., Julien, J-P., Smit, V. T. H. B. M., Tollenaar, R. A. E. M., Mesker, W. E.

Volltext

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC So... von Kroep, J.R., Ouali, M., Gelderblom, H., Le Cesne, A., Dekker, T.J.A., Van Glabbeke, M., Hogendoorn, P.C.W., Hohenberger, P.

Volltext

The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endo... von Waaijer, M. E.C., Lemij, A. A., de Boer, A. Z., Bastiaannet, E., van den Bos, F., Derks, M. G.M., Kroep, J. R., Liefers, G. J., Portielje, J. E.A., de Glas, N. A.

Volltext

Higher ER load is not associated with better outcome in stage 1–3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer von Noordhoek, I., de Groot, A. F., Cohen, D., Liefers, G. J., Portielje, J. E. A., Kroep, J. R.

Volltext

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer von Dekker, T.J.A., Smit, V.T.H.B.M., Hooijer, G.K.J., Van de Vijver, M.J., Mesker, W.E., Tollenaar, R.A.E.M., Nortier, J.W.R., Kroep, J.R.

Volltext

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomis... von Lam, S.W, de Groot, S.M, Honkoop, A.H, Jager, A, ten Tije, A.J, Bos, M.M.E.M, Linn, S.C, van den Bosch, J, Kroep, J.R, Braun, J.J, van Tinteren, H, Boven, E

Volltext

The prognostic role of TGF-β signaling pathway in breast cancer patients von de Kruijf, E.M., Dekker, T.J.A., Hawinkels, L.J.A.C., Putter, H., Smit, V.T.H.B.M., Kroep, J.R., Kuppen, P.J.K., van de Velde, C.J.H., ten Dijke, P., Tollenaar, R.A.E.M., Mesker, W.E.

Volltext

Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan von Fischer, M. J., Inoue, K., Matsuda, A., Kroep, J. R., Nagai, S., Tozuka, K., Momiyama, M., Weijl, N. I., Langemeijer-Bosman, D., Ramai, S. R. S., Nortier, J. W. R., Putter, H., Yamaoka, K., Kubota, K., Kobayashi, K., Kaptein, A. A.

Volltext

Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review von Charehbili, A, Fontein, D.B.Y, Kroep, J.R, Liefers, G.J, Mieog, J.S.D, Nortier, J.W.R, van de Velde, C.J.H

Volltext

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemoth... von de Groot, A. F., Blok, E. J., Charehbili, A., Engels, C. C., Smit, V. T. H. B. M., Dekker-Ensink, N. G., Putter, H., Meershoek-Klein Kranenbarg, E., van de Velde, C. J. H., Liefers, G. J., Nortier, J. W. R., Kuppen, P. J. K., van der Burg, S. H., Kroep, J. R.

Volltext

The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review von de Groot, A.F., Appelman-Dijkstra, N.M., van der Burg, S.H., Kroep, J.R.

Volltext

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival von Santegoets, S. J. A. M., de Groot, A. F., Dijkgraaf, E. M., Simões, A. M. Carnaz, van der Noord, V. E., van Ham, J. J., Welters, M. J. P., Kroep, J. R., van der Burg, S. H.

Volltext

Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy von Rijkmans, E.C, Nout, R.A, Rutten, I.H.H.M, Ketelaars, M, Neelis, K.J, Laman, M.S, Coen, V.L.M.A, Gaarenstroom, K.N, Kroep, J.R, Creutzberg, C.L

Volltext

CDK4/6 inhibition in early and metastatic breast cancer: A review von de Groot, A.F., Kuijpers, C.J., Kroep, J.R.

Volltext

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial von Dekker, T.J.A., Charehbili, A., Smit, V.T.H.B.M., ten Dijke, P., Meershoek-Klein Kranenbarg, E., van de Velde, C.J.H., Nortier, J.W.R., Tollenaar, R.A.E.M., Mesker, W.E., Kroep, J.R.

Volltext

Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision‐making perspective von Pieterse, A.H., Kunneman, M., Engelhardt, E.G., Brouwer, N.J., Kroep, J.R., Marijnen, C.A.M., Stiggelbout, A.M., Smets, E.M.A.

Volltext

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer von van de Ven, S, Smit, V.T.H.B.M, Dekker, T.J.A, Nortier, J.W.R, Kroep, J.R

Volltext

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial) von Post, C.C.B., Westermann, A.M., Boere, I.A., Witteveen, P.O., Ottevanger, P.B., Sonke, G.S., Lalisang, R.I., Putter, H., Meershoek-Klein Kranenbarg, E., Braak, J.P.B.M., Creutzberg, C.L., Bosse, T., Kroep, J.R.

Volltext

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach von Dekker, T. J. A., ter Borg, S., Hooijer, G. K. J., Meijer, S. L., Wesseling, J., Boers, J. E., Schuuring, E., Bart, J., van Gorp, J., Bult, P., Riemersma, S. A., van Deurzen, C. H. M., Sleddens, H. F. B. M., Mesker, W. E., Kroep, J. R., Smit, V. T. H. B. M., van de Vijver, M. J.

Volltext

Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer von Dekker, T.J.A., van de Velde, C.J.H., van Bruggen, D., Mesker, W.E., van der Hoeven, J.J.M., Kroep, J.R., Tollenaar, R.A.E.M., Smit, V.T.H.B.M.

Volltext